Suraksha Diagnostic
- Market cap
- ₹ 1,587 Cr.
- P/E
- 43.5x
- P/B
- 6.15x
- 52-week range
- 224.1 – 360
- ROE
- 14%
- ROCE
- 17%
- Dividend yield
- 0.2%
- Debt / equity
- 0.53
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- NSE, BSE
About
Suraksha Diagnostic Limited is an India-based company. The Company is primarily engaged in the business of running diagnostic centers for carrying out various pathological and radiological services. The Company offers integrated solutions for pathology and radiology testing, and medical consultation services to its customers through its operational network. Its services include Imaging, Neurology, Cardiology, Gastroenterology, and Pathology. Its Imaging services include X-Ray, DEXA scan, USG scan, CT scan and others. Its Neurology services include EEG, EMG, NCV. Its Cardiology services include Echocardiogram Test, Stress Test / Treadmill Test, Holter Monitoring, Color Doppler, Peripheral Doppler, and others. Its Pathology services include Microbiology, Cytogenetic, Serology, Molecular Biology, Histopathology, Cytopathology, Haematology, and others. Its Gastroenterology services include Upper GI Endoscopy, Sigmoidoscopy, Colonoscopy, Proctoscopy, Proctosigmoidoscopy, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Suraksha Diagnostic against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)43.5 against a typical 20.5: pricier than most peers (1st = cheapest).23rd of 34
- Sales growth+20.5% against a typical +19.1% from a year earlier.13th of 31
- Profit growth+44.4% against a typical +25.2% from a year earlier.5th of 24
- Share price, 3 months+24.6% against a typical −7.5%.3rd of 33
- Size₹ 1,587 Cr. market value against a typical ₹ 83 Cr. (1st = largest).7th of 34
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A- by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil A- | Stable | 8 Oct 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 8 Oct 2025 | Rating action | Crisil A- | — | CRISIL | ₹ 250 Cr. |
Research by Minerva Capital Research Solutions
Our research team's work on Suraksha DiagnosticAlso covered in
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 21 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 5 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 10 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 8 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 28 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
| 8 Feb 2025 | Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 52 | 55 | 61 | 67 | 60 | 65 | 73 | 79 | 78 | 81 | 88 |
| Expenses | 39 | 36 | 36 | 40 | 44 | 41 | 46 | 49 | 55 | 55 | 57 | 57 |
| Operating Profit | 21 | 15 | 19 | 21 | 23 | 18 | 19 | 24 | 24 | 23 | 24 | 30 |
| OPM % | 35% | 30% | 35% | 34% | 35% | 31% | 29% | 33% | 31% | 30% | 30% | 35% |
| Other Income | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 |
| Depreciation | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 11 | 11 | 11 |
| Profit before tax | 11 | 6 | 9 | 11 | 14 | 8 | 9 | 12 | 12 | 10 | 10 | 17 |
| Tax % | 24% | 27% | 32% | 27% | 26% | 26% | 22% | 26% | 27% | 28% | 38% | 22% |
| Net Profit | 8 | 5 | 6 | 8 | 10 | 6 | 7 | 9 | 9 | 7 | 6 | 13 |
| EPS in Rs | 121.88 | 67.39 | 94.49 | 1.84 | 2.4 | 1.18 | 1.42 | 1.8 | 1.73 | 1.44 | 1.21 | 2.5 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 17%
- 3 Years
- 18%
- TTM
- 23%
- 10 Years
- —
- 5 Years
- 32%
- 3 Years
- 61%
- TTM
- 8%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 14%
- 3 Years
- 15%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Suraksha Diagnostic | ₹ 312.00 | ₹ 1,587 Cr. | 43.5x | 6.2x | 14% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Somnath Chatterjee
- Executive Chairman of the Board and Joint Managing Director
- Ritu Mittal
- Joint Managing Director and Chief Executive Officer, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.